A narrative mini review in Frontiers in Endocrinology examines how sensory nerves coordinate inflammatory resolution in diabetic wounds through a neuropeptide called calcitonin gene-related peptide, or CGRP. The authors, Jiding Xie, Lei Shi, ShiDong An, Leiyong Wang and Jingang Dai, synthesize findings from experimental diabetic wound models, human tissue samples, acute injury studies and pathogen challenge work.
Almost all of the mechanistic work being summarized is preclinical, carried out in mice and in laboratory assays. Human evidence is limited to tissue observations and a single clinical case report, which matters because the therapeutic platforms described here are nowhere near a clinic.
Why clearance fails
The problem the review centers on is efferocytosis: the process by which macrophages clear dead cells out of a wound. Diabetic mouse wounds show marked reductions in that clearance, so dying neutrophils pile up in the wound bed instead of being removed, which keeps inflammatory signaling switched on and delays healing.
Human diabetic skin specimens show reduced epidermal nerve fiber density and disrupted neuropeptide expression. In mice, genetic ablation of CGRP or blocking its receptor impaired wound-directed angiogenesis and delayed closure, while local replenishment of CGRP in diabetic wounds promoted healing.
The relay nobody should skip
The mechanism runs through a receptor complex requiring RAMP1, and downstream through thrombospondin-1. Knock down Thbs1 in macrophages and CGRP loses its ability to regulate migration, cell death, polarization and efferocytosis entirely, which is about as clean a dependency as preclinical work produces.
But thrombospondin-1 cuts both ways. Through CD47, it inhibits nitric oxide-dependent vasodilation, and the review cautions that whole-wound measurements can hide these opposing effects on microvascular perfusion.
The infection problem
This is the part that should temper enthusiasm. In invasive Streptococcus pyogenes infection, bacterial toxin-driven CGRP release suppressed neutrophil recruitment and paralyzed bacterial killing, and neutralizing CGRP improved clearance and survival. The same pattern appeared in Staphylococcus aureus pneumonia, while in cutaneous Candida albicans infection CGRP signaling was protective.
Diabetic foot ulcers frequently harbor biofilms and polymicrobial pathogens. A therapy that damps local inflammatory signaling could, the authors warn, convert a non-healing ulcer into an invasive infection.
Limitations
Most of the therapeutic studies use splinted excisional wounds in rodents, which do not replicate the chronic stress, mechanical loading and vascular disease of human ulcers. The bioengineered delivery platforms combine CGRP with active carriers, ions and physical stimulation, so closure cannot be attributed to CGRP alone without peptide-free controls and receptor blockade. One human case report described impaired healing in a patient on CGRP-blocking antibodies for migraine, which the review says does not prove the reverse.
Bottom line
Diabetes also damages the recipient phagocytes themselves, so adding more peptide may not restore clearance in cells that have lost the machinery. The review calls CGRP a promising coordinator of leukocyte turnover whose clinical utility depends on durable repair without compromising perfusion or host defense.
Comments (0)
Discussion happens on Reddit.
Go to r/PeptideNewsroomQuestions and corrections go to r/PeptideNewsroom.